Article
Gilead buys out rights to cancer therapy from Jounce for $67 mln
Rating:
0.0
Views:
45
Likes:
1
Library:
1
Gilead Sciences will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics for $67 million, the drugmaker said on Tuesday.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value